The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index, and 1 are not checked yet.
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Open accessPublished version of a preprint
Abstract
The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein 1-5 show promise therapeutically and are being evaluated clinically 6-8. Here, to identify the structural correlates of SARS-CoV-2 neutralization, we solved eight new structures of distinct COVID-19 human neutralizing antibodies 5 in complex with the SARS-CoV-2 spike trimer or RBD. Structural comparisons allowed us to classify the antibodies into categories: (1) neutralizing antibodies encoded by the VH3-53 gene segment with short CDRH3 loops that block ACE2 and bind only to 'up' RBDs; (2) ACE2-blocking neutralizing antibodies that bind both up and 'down' RBDs and can contact adjacent RBDs; (3) neutralizing antibodies that bind outside the ACE2 site and recognize both up and down RBDs; and (4) previously described antibodies that do not block ACE2 and bind only to up RBDs 9. Class 2 contained four neutralizing antibodies with epitopes that bridged RBDs, including a VH3-53 antibody that used a long CDRH3 with a hydrophobic tip to bridge between adjacent down RBDs, thereby locking the spike into a closed conformation. Epitope and paratope mapping revealed few interactions with host-derived N-glycans and minor contributions of antibody somatic hypermutations to epitope contacts. Affinity measurements and mapping of naturally occurring and in vitro-selected spike mutants in 3D provided insight into the potential for SARS-CoV-2 to escape from antibodies elicited during infection or delivered therapeutically. These classifications and structural analyses provide rules for assigning current and future human RBD-targeting antibodies into classes, evaluating avidity effects and suggesting combinations for clinical use, and provide insight into immune responses against SARS-CoV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, antibodies that share the same combination of IGHV and IGLV genes in vaccinees comprised 39% of all the clonal sequences (Extended Data Fig. 4b) and 59% when combined with naturally infected individuals7,8 (Fig. 2f), and some of these antibodies were nearly identical (Extended Data Table 3 and 4).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The T478K mutation in the RBD is unique to the Delta variant and falls within the epitope region of potent neutralizing monoclonal antibodies categorized as 'Class1' 17”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“As expected, plasma neutralizing activity was directly correlated to anti-S and -RBD binding titers in ELISAs7,8 (Fig. 1c, d, and Extended Data Fig. 2a–d).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Moreover, the plasma neutralizing activity, and the relative numbers of RBD-specific memory B cells were equivalent to individuals who recovered from natural infection7,8.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Although circulating antibodies derived from plasma cells wane over time, long-lived immune memory can persist in expanded clones of memory B cells7,20.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“As seen in natural infection, a majority of the antibodies tested (9/17) were at least ten-fold less effective against pseudotyped viruses carrying the E484K mutation7,12,29.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“In anti-RBD ELISAs the mean half-maximal effective concentration (EC50) was higher than that observed in infected individuals after 6.2 months but not significantly different from antibodies obtained 1.3 months after infection (Extended Data Fig. 6a, and Table 5 and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Class 1 and 2 antibodies are among the most potent and also the most abundant antibodies7,8,21,22,25,39.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Consistent with the plasma neutralization results, the geometric mean neutralization half-maximal inhibitory concentration of the Pfizer-BioNTech and Moderna vaccinee antibodies were not significantly different from each other or to antibody collections obtained from naturally infected individuals 1.3 or 6.2 months after infection (Fig. 3a and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“In contrast to the earlier time point, 13 of 15 neutralizing antibodies obtained after 12 months interfered only with C121, a class 2 antibody3,23 (Fig. 4c, Extended Data Fig. 9).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [23]
In the citing paper
“Residue S477 is close to the receptor binding site (Fig ED2) and part of the epitope recognized by the S2E12 and C102 neutralizing antibodies 17,18 .”
From Spread of a SARS-CoV-2 variant through Europe in the summer of 2020 (2021) · cites this paper as [17]
In the citing paper
“a potent Ab that can recognize both “up” and “down” SARS-CoV-2 RBD conformations [41].”
From Deep geometric representations for modeling effects of mutations on protein-protein binding affinity (2021) · cites this paper as [41]
In the citing paper
“Importantly, our spike did not contain R346K, which has been observed at relatively low frequency (<10%) within the Omicron lineage, but which is known to mediate escape from class 3 neutralizing monoclonal antibodies such as AZD1061/cilgavimab (Barnes et al., 2020; Dong et al., 2021; Greaney et al., 2021b).”
From mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2022) · cites this paper as Barnes et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Cited by
Sorted by citations
Items 301–400 of 1,004
Du, W., Hurdiss, D. L., Drabek, D., Mykytyn, A. Z., Kaiser, F. K., González-Hernández, M., Muñoz‐Santos, D., Lamers, M. M., van Haperen, R., Li, W., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp9312 · Cited by 56
Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2
Huang, K.-Y. A., Chen, X., Mohapatra, A., Nguyen, H. T. V., Schimanski, L. M., Tan, T. K., Rijal, P., Vester, S. K., Hills, R. A., Howarth, M. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35949-8 · Cited by 51
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
Martinez, D. R., Schäfer, A., Leist, S. R., Li, D., Gully, K. L., Yount, B. L., Feng, J. Y., Bunyan, E., Porter, D., Cihlář, T., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109450 · Cited by 48
Self-citationLuo, S., Zhang, J., Kreutzberger, A. J. B., Eaton, A., Edwards, R. J., Jing, C., Dai, H., Sempowski, G. D., Cronin, K. D., Parks, R., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.add5446 · Cited by 53
Monoclonal antibodies: From magic bullet to precision weapon
Aboul-Ella, H., Gohar, A., Ali, A. A., Ismail, L. M., Mahmoud, A. E. E.-R., Elkhatib, W. F., & Aboul-Ella, H. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00210-1 · Cited by 66
Wang, C., Hesketh, E. L., Shamorkina, T. M., Li, W., Franken, P. J., Drabek, D., van Haperen, R., Townend, S., van Kuppeveld, F. J. M., Grosveld, F. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30658-0 · Cited by 52
Pushparaj, P., Nicoletto, A., Sheward, D. J., Das, H., Dopico, X. C., Vidakovics, L. P., Hanke, L., Chernyshev, M., Narang, S., Kim, S., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.12.005 · Cited by 51
Ju, B., Zhang, Q., Wang, Z., Aw, Z. Q., Chen, P., Zhou, B., Wang, R., Ge, X., Lv, Q., Cheng, L., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01449-6 · Cited by 50
SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequences
Wang, X., Lu, L., & Jiang, S. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.01.003 · Cited by 51
Nel, A. E., & Miller, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.1c01845 · Cited by 50
One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening
Francino-Urdaniz, I. M., Steiner, P. J., Kirby, M. B., Zhao, F., Haas, C. M., Barman, S., Rhodes, E. R., Leonard, A. C., Peng, L., Sprenger, K. G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109627 · Cited by 47
An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses
Liu, L., Iketani, S., Guo, Y., Reddem, E. R., Casner, R. G., Nair, M. S., Yu, J., Chan, J. F., Wang, M., Cerutti, G., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn6859 · Cited by 51
On the road to ending the COVID-19 pandemic: Are we there yet?
Case, J. B., Winkler, E. S., Errico, J. M., & Diamond, M. (2021) · Virology · doi:10.1016/j.virol.2021.02.003 · Cited by 47
Protective neutralizing epitopes in SARS‐CoV‐2
Liu, H., & Wilson, I. A. (2022) · Immunological Reviews · doi:10.1111/imr.13084 · Cited by 49
Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals
Cohen, A. A., Keeffe, J. R., Schiepers, A., Dross, S., Greaney, A. J., Rorick, A. V., Gao, H., Gnanapragasam, P. N. P., Fan, C., West, A. P., et al. (2024) · Cell · doi:10.1016/j.cell.2024.07.052 · Cited by 51
Self-citationSARS-CoV-2 spike protein: structure, viral entry and variants
Chen, B., Farzan, M., & Choe, H. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01185-8 · Cited by 57
Ochoa, S., & Milam, V. T. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.5c00196 · Cited by 50
Ellis, D., Brunette, N., Crawford, K. H. D., Walls, A. C., Pham, M. N., Chen, C., Herpoldt, K., Fiala, B., Murphy, M., Pettie, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710263 · Cited by 45
Valdez‐Cruz, N. A., García‐Hernández, E., Espitia, C., Cobos-Marín, L., Altamirano, C., Bando-Campos, C. G., Cofas‐Vargas, L. F., Coronado-Aceves, E. W., González-Hernández, R. A., Hernández‐Peralta, P., et al. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01576-5 · Cited by 52
Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies
Wang, J. J., Zhang, N., Richardson, S. A., & Wu, J. V. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1913123 · Cited by 49
Monoclonal Antibody Therapeutics for Infectious Diseases: Beyond Normal Human Immunoglobulin
Otsubo, R., & Yasui, T. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108233 · Cited by 55
Ku, Z., Xie, X., Lin, J., Gao, P., Wu, B., Sahili, A. E., Su, H., Liu, Y., Ye, X., Tan, E. Y. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33284-y · Cited by 54
Tai, W., Yang, K., Liu, Y., Li, R., Feng, S., Chai, B., Zhuang, X., Qi, S., Shi, H., Liu, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43798-8 · Cited by 52
Marcotte, H., Cao, Y., Zuo, F., Simonelli, L., Sammartino, J. C., Pedotti, M., Sun, R., Cassaniti, I., Hagbom, M., Piralla, A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2315354120 · Cited by 53
Self-citationXiang, Y., Xu, J., McGovern, B. L., Ranzenigo, A., Huang, W., Sang, Z., Shen, J., Diaz-Tapia, R., Pham, N. D., Teunissen, A. J. P., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.043 · Cited by 48
Verkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00372 · Cited by 40
Cheng, M. H., Krieger, J., Banerjee, A., Xiang, Y., Kaynak, B., Shi, Y., Arditi, M., & Bahar, İ. (2022) · iScience · doi:10.1016/j.isci.2022.103939 · Cited by 50
Brüssow, H. (2020) · Environmental Microbiology · doi:10.1111/1462-2920.15302 · Cited by 54
SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients
Schwarz, T., Heiß, K., Mahendran, Y., Casilag, F., Kurth, F., Sander, L. E., Wendtner, C., Hoechstetter, M. A., Müller, M. A., Sekul, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.629185 · Cited by 45
Upadhyay, V., Lucas, A., Panja, S., Miyauchi, R., & Mallela, K. M. G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101208 · Cited by 44
Maeda, R., Fujita, J., Konishi, Y., Kazuma, Y., Yamazaki, H., Anzai, I., Watanabe, T., Yamaguchi, K., Kasai, K., Nagata, K., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03630-3 · Cited by 47
Yang, W.-T., Huang, W.-H., Liao, T.-L., Hsiao, T.-H., Chuang, H.-N., & Liu, P.-Y. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s344099 · Cited by 51
Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
Maeda, K., Higashi‐Kuwata, N., Kinoshita, N., Kutsuna, S., Tsuchiya, K., Hattori, S.-I., Matsuda, K., Takamatsu, Y., Gatanaga, H., Oka, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84733-5 · Cited by 44
Li, T., Han, X., Gu, C., Guo, H., Zhang, H., Wang, Y., Hu, C., Wang, K., Liu, F., Luo, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26539-7 · Cited by 45
The Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?
Guo, S., Liu, K., & Zheng, J. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59137 · Cited by 46
Seow, J., Khan, H., Rosa, A., Calvaresi, V., Graham, C., Pickering, S., Pye, V. E., Cronin, N., Huettner, I., Malim, M. H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111276 · Cited by 41
Yang, L., Beek, M. V., Wang, Z., Muecksch, F., Canis, M., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., & Chakraborty, A. K. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112256 · Cited by 50
Self-citationStewart-Jones, G., Elbashir, S. M., Wu, K., Lee, D., Renzi, I., Ying, B., Koch, M., Sein, C. E., Choi, A., Whitener, B. M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf4100 · Cited by 55
The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune escape, and response strategies
Lu, Y., Ao, D., He, X., & Wei, X. (2024) · MedComm · doi:10.1002/mco2.675 · Cited by 46
Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses
Park, Y., Liu, C., Lee, J., Brown, J. T., Ma, C., Liu, P., Gen, R., Xiong, Q., Zepeda, S. K., Stewart, C., et al. (2025) · Cell · doi:10.1016/j.cell.2024.12.032 · Cited by 47
SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses
Carnell, G., Ciazynska, K. A., Wells, D. A., Xiong, X., Aguinam, E. T., McLaughlin, S. H., Mallery, D. L., Ebrahimi, S., Ceron‐Gutierrez, L., Asbach, B., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00203-21 · Cited by 46
Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview
Mehra, R., & Kepp, K. P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00433 · Cited by 45
Robinson, S. A., Raybould, M. I. J., Schneider, C., Wong, W. K., Marks, C., & Deane, C. M. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009675 · Cited by 46
Noval, M. G., Kaczmarek, M. E., Koide, A., Rodriguez-Rodriguez, B. A., Louie, P., Tada, T., Hattori, T., Panchenko, T., Romero, L. A., Teng, K. W., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84913-3 · Cited by 53
Chakraborty, C., Bhattacharya, M., & Sharma, A. R. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.006 · Cited by 45
The Development of SARS-CoV-2 Variants: The Gene Makes the Disease
Pérez-Gómez, R. (2021) · Journal of Developmental Biology · doi:10.3390/jdb9040058 · Cited by 47
Ohishi, T., Hishiki, T., Baig, M. S., Rajpoot, S., Saqib, U., Takasaki, T., & Hara, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271112 · Cited by 48
A biophysical model of viral escape from polyclonal antibodies
Yu, T. C., Thornton, Z., Hannon, W. W., DeWitt, W. S., Radford, C. E., Matsen, F. A., IV, & Bloom, J. D. (2022) · Virus Evolution · doi:10.1093/ve/veac110 · Cited by 42
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Dijokaite-Guraliuc, A., Das, R., Zhou, D., Ginn, H. M., Liu, C., Duyvesteyn, H. M. E., Huo, J., Nutalai, R., Supasa, P., Selvaraj, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112271 · Cited by 46
Miersch, S., Li, Z., Saberianfar, R., Ustav, M., Case, J. B., Blazer, L. L., Chen, C., Ye, W., Pavlenco, A., Gorelik, M., et al. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167177 · Cited by 45
Zimmerman, M. I., Porter, J. R., Ward, M. D., Singh, S., Vithani, N., Meller, A., Mallimadugula, U. L., Kuhn, C. E., Borowsky, J. H., Wiewiora, R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.27.175430 · Cited by 45
SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies
Mlčochová, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Mishra, S., Whittaker, C., Mellan, T. A., Ferreira, I., Datir, R. P., et al. (2021) · Greater South Information System · doi:10.60692/dy28a-h7650 · Cited by 44
Burnett, D. L., Jackson, K., Langley, D. B., Aggarwal, A., Stella, A. O., Johansen, M. D., Balachandran, H., Lenthall, H., Rouet, R., Walker, G. J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.019 · Cited by 45
Henriquez, S., Zerbit, J., Bruel, T., Ouedrani, A., Planas, D., Deschamps, P., Staropoli, I., Hadjadj, J., Varet, B. R., Suarez, F., et al. (2021) · Blood · doi:10.1182/blood.2021013714 · Cited by 44
Hofmann, N., Grossegesse, M., Neumann, M., Schaade, L., & Nitsche, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-07597-3 · Cited by 43
COVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 48
Rossotti, M. A., van Faassen, H., Tran, A., Sheff, J. G., Sandhu, J. K., Duque, D., Hewitt, M., Wen, X., Bavananthasivam, J., Beitari, S., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03866-z · Cited by 45
SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants
Hattab, D., Amer, M. F. A., Al‐Alami, Z. M., & Bakhtiar, A. (2024) · Infection · doi:10.1007/s15010-024-02223-y · Cited by 48
Voss, W. N., Mallory, M. L., Byrne, P. O., Marchioni, J., Knudson, S. A., Powers, J. M., Leist, S. R., Dadonaite, B., Townsend, D. R., Kain, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101668 · Cited by 44
50 Years of structural immunology
Wilson, I. A., & Stanfield, R. L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100745 · Cited by 44
Inoue, T., Shinnakasu, R., Chie, K., Yamamoto, H. H., Sakakibara, S., Ono, C., Itoh, Y., Terooatea, T. W., Yamashita, K., Okamoto, T., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221786 · Cited by 46
Touret, F., Giraud, É., Bourret, J., Donati, F., Tran-Rajau, J., Chiaravalli, J., Lemoine, F., Agou, F., Simon‐Lorière, E., van der Werf, S., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106413 · Cited by 42
Engdahl, T. B., Binshtein, E., Brocato, R. L., Kuzmina, N. A., Principe, L. M., Kwilas, S. A., Kim, R. K., Chapman, N. S., Porter, M. S., Guardado‐Calvo, P., et al. (2023) · eLife · doi:10.7554/elife.81743 · Cited by 43
Liu, Y., Wang, Z., Zhuang, X., Zhang, S., Chen, Z., Zou, Y., Sheng, J., Li, T., Tai, W., Yu, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37926-7 · Cited by 43
Guenthoer, J., Lilly, M., Starr, T. N., Dadonaite, B., Lovendahl, K. N., Croft, J. T., Stoddard, C. I., Chohan, V., Ding, S., Ruiz, F., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220948120 · Cited by 39
Conformational flexibility and structural variability of SARS-CoV2 S protein
Pramanick, I., Sengupta, N., Mishra, S., Pandey, S., Girish, N., Das, A., & Dutta, S. (2021) · Structure · doi:10.1016/j.str.2021.04.006 · Cited by 43
Wu, D., Kolesnikov, A. V., Yin, R. M., Guest, J. D., Gowthaman, R., Shmelev, A., Serdyuk, Y. V., Dianov, D. V., Efimov, G. A., Pierce, B. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27669-8 · Cited by 45
Shi, Y., Zeida, A., Edwards, C. E., Mallory, M. L., Sastre, S., Machado, M. R., Pickles, R. J., Fu, L. L., Liu, K., Yang, J. H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120419119 · Cited by 43
Monoclonal antibody therapies in the management of SARS-CoV-2 infection
Rey, E. M., Choi, D., Kim, S., Yoon, S., & Săndulescu, O. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2030310 · Cited by 46
Mikolajek, H., Weckener, M., Brotzakis, Z. F., Huo, J., Dalietou, E. V., Bas, A. L., Sormanni, P., Harrison, P. J., Ward, P. N., Truong, S. D., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205412119 · Cited by 39
Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies
Almagro, J. C., Mellado‐Sánchez, G., Pedraza‐Escalona, M., & Pérez‐Tapia, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179763 · Cited by 40
Symptomatic reinfection of SARS‐CoV‐2 with spike protein variant N440K associated with immune escape
Pallavali, R. R., Imran, M., Lakshmi, J. V., Jolly, B., Jain, A. K., Surekha, A., Senthivel, V., Chandrasekhar, P., Divakar, M. K., Srinivasulu, D., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26997 · Cited by 42
Capone, F., Lucchini, M., Ferraro, E., Bianco, A. D., Rossi, M., Cicia, A., Cortese, A., Cruciani, A., Arcangelis, V. D., Giglio, L. D., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01165-9 · Cited by 42
Kumar, S., Patel, A. B., Lai, L., Chennareddy, C., Valanparambil, R. M., Reddy, E. S., Gottimukkala, K. P., Davis-Gardner, M. E., Edara, V. V., Linderman, S. L., et al. (2022) · Science Advances · doi:10.1126/sciadv.add2032 · Cited by 41
Tran, T. T., Vaage, E. B., Mehta, A., Chopra, A., Tietze, L., Kolderup, A., Anthi, A. K., König, M. S. S., Nygaard, G. O., Lind, A., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00586-7 · Cited by 47
SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity
Zhang, F., Schmidt, F., Muecksch, F., Wang, Z., Gazumyan, A., Nussenzweig, M. C., Gaebler, C., Caskey, M. F., Hatziioannou, T., & Bieniasz, P. D. (2024) · mBio · doi:10.1128/mbio.01672-23 · Cited by 46
Self-citationPan, Y., Du, J., Liu, J., Wu, H., Gui, F., Zhang, N., Deng, X., Song, G., Li, Y., Lu, J., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00295-w · Cited by 44
Ma, H., Zhang, X., Zheng, P., Dube, P. H., Zeng, W., Chen, S., Cheng, Q., Yang, Y., Wu, Y., Zhou, J., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00700-3 · Cited by 42
Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective
Huang, Y., Sun, H., Yu, H. J., Li, S., Zheng, Q., & Xia, N. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa028 · Cited by 40
Socher, E., Heger, L., Paulsen, F. P., Zunke, F., & Arnold, P. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.02.015 · Cited by 38
Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS‐CoV‐2 Variants
Zupancic, J. M., Schardt, J. S., Desai, A. A., Makowski, E. K., Smith, M. D., Pornnoppadol, G., Barbosa, M. G. D. M., Cascalho, M., Lanigan, T. M., & Tessier, P. M. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100099 · Cited by 40
Destoumieux‐Garzón, D., Matthies‐Wiesler, F., Bierne, N., Binot, A., Boissier, J., Devouge, A., Garric, J., Gruetzmacher, K., Grunau, C., Guégan, J., et al. (2021) · Environment International · doi:10.1016/j.envint.2021.106915 · Cited by 44
Cross-Species Tropism and Antigenic Landscapes of Circulating SARS-CoV-2 Variants
Zhang, Y., Wei, M., Wu, Y., Wang, J., Hong, Y., Huang, Y., Yuan, L., Ma, J., Wang, K., Wang, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2022.110558 · Cited by 40
Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor
Capraz, T., Kienzl, N. F., Laurent, E., Perthold, J. W., Föderl-Höbenreich, E., Grünwald‐Gruber, C., Maresch, D., Monteil, V., Niederhöfer, J., Wirnsberger, G., et al. (2021) · eLife · doi:10.7554/elife.73641 · Cited by 39
IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2
Hale, M. R., Netland, J., Chen, Y., Thouvenel, C. D., Smith, K. N., Rich, L. M., Vanderwall, E. R., Miranda, M. C., Eggenberger, J., Hao, L., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220849 · Cited by 43
Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine DosePreprint
Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Tanfous, T. B., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.14.480394 · Cited by 41
Self-citationRouet, R., Henry, J. Y., Johansen, M. D., Sobti, M., Balachandran, H., Langley, D. B., Walker, G. J., Lenthall, H., Jackson, J., Ubiparipovic, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36295-5 · Cited by 41
Vishwanath, S., Carnell, G., Ferrari, M., Asbach, B., Billmeier, M., George, C. L., Sans, M. S., Nadesalingam, A., Huang, C. Q., Paloniemi, M., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01094-2 · Cited by 40
Jia, Z., Wang, K., Xie, M., Wu, J., Hu, Y., Zhou, Y., Yisimayi, A., Fu, W., Wang, L., Liu, P., et al. (2024) · Protein & Cell · doi:10.1093/procel/pwae033 · Cited by 41
Malladi, S. K., Patel, U. R., Rajmani, R. S., Singh, R., Pandey, S., Kumar, S., Khaleeq, S., van Vuren, P. J., Riddell, S., Goldie, S., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00276 · Cited by 38
Ahmad, J., Jiang, J., Boyd, L. F., Zeher, A., Huang, R. K., Xia, D., Natarajan, K., & Margulies, D. H. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101202 · Cited by 38
Principles of SARS-CoV-2 glycosylation
Chawla, H., Fadda, E., & Crispin, M. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102402 · Cited by 40
Wang, K., Cao, Y., Zhou, Y., Wu, J., Jia, Z., Hu, Y., Yisimayi, A., Fu, W., Wang, L., Liu, P., et al. (2021) · medRxiv · doi:10.1101/2021.09.02.21261735 · Cited by 40
Martin, D. P., Lytras, S., Lucaci, A. G., Maier, W., Grüning, B. A., Shank, S. D., Weaver, S., MacLean, O. A., Orton, R. J., Lemey, P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.14.476382 · Cited by 40
Wang, Q., Guo, Y., Bowen, A. D., Mellis, I. A., Valdez, R., Gherasim, C., Gordon, A. L., Liu, L., & Ho, D. D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.26.568730 · Cited by 40
Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Lorenzi, J. C. C., Flyak, A. I., DeLaitsch, A. T., Huey-Tubman, K. E., Hou, S., et al. (2021) · doi:10.1101/2021.03.07.434227 · Cited by 39
Self-citationYang, Z., Wang, Y., Jin, Y., Zhu, Y., Wu, Y., Li, C., Kong, Y., Song, W., Tian, X., Zhan, W., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00810-1 · Cited by 37
Yu, Y., Esposito, D., Kang, Z., Lü, J., Remaley, A. T., Giorgi, V. D., Chen, L. N., West, K. A., & Cao, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-06629-2 · Cited by 40
Nucleic acid testing of SARS-CoV-2: A review of current methods, challenges, and prospects
Zhu, Y., Zhang, M., Jie, Z., & Tao, S. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1074289 · Cited by 39
Metadata
- Authors
- Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., Robbiani, D. F., Nussenzweig, M. C., West, A. P., & Bjorkman, P. J.
- Affiliations
- California Institute of Technology (US)
- Institute for Research in Biomedicine (CH)
- Howard Hughes Medical Institute (US)
- ORCID
- Venue
- Nature
- Published
- 2020-10-12
- Volume
- 588
- Issue
- 7839
- Pages
- 682-687
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8092461
- OpenAlex
- W3092403777
- Cited by
- 1,599
- References
- 70
- Citations by year
- 2026: 94 · 2025: 121 · 2024: 181 · 2023: 267 · 2022: 448 · 2021: 440 · 2020: 35
- FWCI
- 39.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-04-02)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- U.S. Department of Energy (P41GM103393, DE-AC02-)
- Burroughs Wellcome Fund
- George Mason University
- California Institute of Technology
- Wellcome Trust
- National Institutes of Health (AI138938, P01 AI138938-S1, AI150464)
- Office of Science (P41GM103393, DE-AC02)
- Beckman Institute, California Institute of Technology
- National Institute of General Medical Sciences (AI150464, P41GM103393)
- National Institute of Allergy and Infectious Diseases (P50AI150464, F30AI147579, P01AI138938)
- Basic Energy Sciences (DE-AC02, P41GM103393)
- Biological and Environmental Research (P41 GM103393)
- SLAC National Accelerator Laboratory (P41GM103393)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, spike protein receptor-binding domain, antibody-antigen complex structure, ACE2 receptor, epitope mapping, N-glycans, somatic hypermutation, antibody escape, avidity, antibody combination therapy, spike trimer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
